On September 7, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, reported that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences in September (Press release, Aldeyra Therapeutics, SEP 7, 2022, View Source [SID1234619188]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 17th Annual BioPharma Conference (1×1 meetings only)
Wednesday, September 7, 2022
Boston, Mass.
H.C. Wainwright 24th Annual Global Investment Conference
Wednesday, September 14, 2022
New York, NY
Dr. Brady’s presentation at the H.C. Wainwright 24th Annual Global Investment Conference is scheduled to begin at 10:00 a.m. ET Wednesday, September 14, 2022. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at View Source A replay will be available following the presentation and will be archived on the website for 90 days.

On September 7, 2022 RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, reported management’s participation in the upcoming H.C. Wainwright 24th Annual Global Investment Conference (Press release, Renovorx, SEP 7, 2022, View Source [SID1234619187]). This conference is to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Shaun Bagai, RenovoRx’s CEO, will provide a corporate update during his presentation. He will also discuss current available treatment options for pancreatic tumors, why they can fall short of providing an effective solution for treating this deadly disease, and how RenovoRx’s therapy platform re-envisions the treatment of pancreatic and other difficult-to-treat cancers. During the Conference, Shaun will participate in one-on-one meetings with the investment community. Attendees include public companies, and institutional and private investors. To schedule a meeting, please reach out to your H.C. Wainwright representative or send an email to KCSA Strategic Communications at [email protected].

H.C. Wainwright Global Investment Conference
Title: A Late-Stage Biopharmaceutical Company with an Innovative Therapy for Targeted Treatment Of Difficult-to-Treat Cancer
Format and Dates: Hybrid, September 12-14, 2022
Location: Lotte New York Palace Hotel, New York, New York
Presenter: Shaun Bagai, CEO
Presentation Date and Time: Monday, September 12th at 7:00 a.m. ET
Webcast: View Source
Replay Available: A recording of the event will be posted to RenovoRx Website Events page for 90 days after the event

On September 7, 2022 Exscientia (Nasdaq: EXAI) reported that Company management will participate in the following investor conferences in September (Press release, Exscientia, SEP 7, 2022, View Source [SID1234619185]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley Annual Global Healthcare Conference:
Date: Wednesday, September 14, 2022
Time: 3:35 p.m. BST / 10:35 a.m. EST
Location: New York, New York
Participants: Ben Taylor, CFO & Chief Strategy Officer and Dave Hallett, Chief Operations Officer

BofA Securities Global Healthcare Conference:
Date: Thursday, September 15, 2022
Time: 3:05 p.m. BST / 10:05 a.m. EST
Location: London, United Kingdom
Participants: Andrew Hopkins, DPhil., Exscientia’s founder and CEO, and Garry Pairaudeau, Chief Technology Officer

Live webcasts of the presentations will be available on the Company’s website, under the "Investors & Media" section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

On September 7, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that Phase 2 data evaluating the safety of suprachoroidal administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (IL/CM)) will be presented at the ESMO (Free ESMO Whitepaper) 2022 Congress, being held September 9-13, 2022, in Paris, France (Press release, Aura Biosciences, SEP 7, 2022, View Source [SID1234619184]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for ESMO (Free ESMO Whitepaper) 2022 poster presentation:

Title: A Phase 2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration
Presenter: Hakan Demirci, University of Michigan
Session: Melanoma and Other Skin Tumors
Presentation #: 842P
Date/Time: Saturday, September 10, 2022, at 2:15 p.m. CEST

The presentation will be available on the "Scientific Presentations" section of "VDC Platform" page of the Aura Biosciences website on Saturday, September 10, 2022.

On September 7, 2022 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, reported that members of its senior management team will participate at two investor conferences in September (Press release, Repare Therapeutics, SEP 7, 2022, View Source [SID1234619183]). Details for the fireside chats are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Time: 2:55 p.m. Eastern Time
Location: New York, NY

Guggenheim Nantucket Therapeutics Conference
Date: Wednesday, September 28, 2022
Time: 8:00 a.m. Eastern Time
Location: Nantucket, MA

A live webcast of the fireside chats can be accessed in the Investor section of the Company’s website at View Source A replay of the webcasts will be archived on the Company’s website for 90 days.